The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma

The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation

(2018) Wenwen Xu et al.   Cellular & Molecular Immunology

Immunoregulatory functions of VISTA

(2017) Elizabeth C. Nowak et al.   IMMUNOLOGICAL REVIEWS

Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping

(2017) Moritz Jesinghaus et al.   Oncotarget

The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?

(2017) Christine Böger et al.   OncoImmunology

Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas

(2016) Doris Helbig et al.   Oncotarget

VISTA Is an Immune Checkpoint Molecule for Human T Cells

(2014) J. L. Lines et al.   CANCER RESEARCH

VISTA Regulates the Development of Protective Antitumor Immunity

(2014) I. Le Mercier et al.   CANCER RESEARCH

VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy

(2014) J. L. Lines et al.   Cancer Immunology Research

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

(2012) Douglas G Altman et al.   BMC Medicine

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Response Evaluation by Endoscopy, Rebiopsy, and Endoscopic Ultrasound Does Not Accurately Predict Histopathologic Regression After Neoadjuvant Chemoradiation for Esophageal Cancer

(2008) Paul M. Schneider et al.   ANNALS OF SURGERY